Retired electrician Joe Walsh in December became the first Alzheimer’s patient to try a nasal spray used to treat other ...

There’s another recall to be aware of right now, and it involves nose spray. NeilMed Pharmaceuticals Inc., the manufacturer of NasoGel Spray, has issued an international recall of 89,312 of its sprays ...

OKAY, HONEY, COME SIT HERE. TODAY, JOE IS TESTING SOMETHING NEW. A MEDICATION CALLED FOR INSIDE THIS NASAL SPRAY. ONE, TWO. THREE. JOE IS THE FIRST PATIENT WITH ALZHEIMER’S TO TRY THIS DRUG.

9NEWS Medical Expert Dr. Payal Kohli weighs in on a new nasal spray being used to treat depression. 14 Outdated Home Trends That Are Lowering Your Property Value ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions ... and only monotherapy for adults living with major depressive disorder who ...

21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant ... adults in the United States living with the disease, according to ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment ...

The nasal spray can be given to people who haven’t seen improvements to their depression after taking at least two oral medications, according to Johnson & Johnson. The main ingredient for the ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...